Health care and burden of illness in systemic lupus erythematosus compared to rheumatoid arthritis: results from the national database of the German Collaborative Arthritis Centres

Abstract

During the past 20 years, outcome studies in the rheumatic diseases have, on the one hand, given increasing evidence of the unfavourable long-term prognosis of rheumatoid arthritis (RA) and on the other hand determined continuous improvement of prognosis in systemic lupus erythematosus (SLE). The aim of the study was to investigate how this translates into the current spectrum of patients with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE) seen by rheumatologists in Germany and to compare aspects of the burden of disease, disease outcomes and treatment between these two important rheumatic diseases using a large clinical database. Current health care was analysed with data from the German rheumatological database of 10 068 patients with RA and 1248 patients with SLE seen by rheumatologists in 2001. In addition, of a total of 3546 patients with SLE and 24 969 patients with RA seen at the German Collaborative Arthritis Centres between 1994 and 2001, 3465 cases of SLE were matched by age, sex, disease duration and referral status with a corresponding RA case. There were considerable differences in treatment of patients before referral to a rheumatologist and in rheumatologic care. In 2001, patients with SLE were treated by their rheumatologists mainly with antimalarials (AM, 37%), azathioprine (29%) and nonselective NSAIDs (16%). Of them, 61% received at least one immunosuppressive drug (including AM) plus glucocorticoids. In RA, methotrexate was the predominant medication (63%), and 56% received at least one immunosuppressive drug plus glucocorticoids. Matched pairs analysis showed that SLE patients with a short disease duration were almost equally burdened by pain, functional limitations and reduced health status as RA patients. After a disease duration of .10 years, however, patients with RA showed poorer outcomes than those with SLE: RA patients reported significantly more often severe pain (30% in RA versus 17% in SLE) and poor global health status (52 versus 38%), and their disease activity as well as severity was rated higher by the rheumatologists. In conclusion, comparing large groups of RA and SLE patients we found a similar burden in early but not in late disease. Taking into account limitations as to the generalizability of the results (recruitment in rheumatologic care, cross-sectional data, underestimation of SLE-specific outcomes), the discrepancy between the high increase in disease-related negative outcomes with longer disease duration in RA but not in SLE indicates a better long-term prognosis in SLE concerning the items observed. The great disparity in treatment intensity between rheumatologists and nonrheumatologists shows that the involvement of a specialist is needed equally in both diseases.

Keywords

burden of illness health care national database rheumatoid arthritis systemic lupus erythematosus

Get full access to this article

View all access options for this article.

References

Symmons D , Turner G , Webb R et al. The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century . Rheumatology (Oxford) 2002; 41: 793-800 .

Silman A. Rheumatoid arthritis. In Silman A , Hochberg M eds. Epidemiology of the rheumatic diseases. Oxford: Oxford University Press , 2001: 31-71.

Goodson N , Symmons D. Rheumatoid arthritis in women: still associated with an increased mortality . Ann Rheum Dis 2002; 61: 955-956 .

Choi HK , Hernan MA , Seeger JD , Robins JM , Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study . Lancet 2002; 359: 1173-1177 .

Krause D , Schleusser B , Herborn G , Rau R. Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis . Arthritis Rheum 2000; 43: 14-21 .

Myllykangas-Luosujarvi RA , Aho K , Isomaki HA. Mortality in rheumatoid arthritis . Semin Arthritis Rheum 1995; 25: 193-202 .

Ward M , Pyun E , Studenski S. Long-term survival in systemic lupus erythematosus. Patient characteristics associated with poorer outcomes . Arthritis Rheum 1995; 38: 274-283 .

Urowitz MB , Abu-Shakra M , Gladman DD et al. Improved survival in SLE . J Rheumatol 1997; 24: 1061-1065 .

Abu-Shakra M , Urowitz MB , Gladman DD , Gough J. Mortality studies in systemic lupus erythematosus. Results from a single center. II. Predictor variables for mortality . J Rheumatol 1995; 22: 1265-1270 .

10.

Manger K , Manger B , Repp R et al. Definition of risk factors for death, end stage renal disease, and thromboembolic events in a monocentric cohort of 338 patients with systemic lupus erythematosus . Ann Rheum Dis 2002; 61: 1065-1070 .

11.

Fortin PR , Abrahamowicz M , Neville C et al. Impact of disease activity and cumulative damage on the health of lupus patients . Lupus 1998; 7: 101-107 .

12.

Burckhardt CS , Archenholtz B , Bjelle A. Quality of life of women with systemic lupus erythematosus: a comparison with women with rheumatoid arthritis . J Rheumatol 1993; 20: 977-981 .

13.

Gilboe I , Kvien TK , Husby G. Health status in systemic lupus erythematosus compared to rheumatoid arthritis and healthy controls . J Rheumatol 1999; 26: 1694-1700 .

14.

Uramoto KM , Michet CJ Jr , Thumboo J , Sunku J , O’Fallon WM , Gabriel SE. Trends in the incidence and mortality of systemic lupus erythematosus, 1950-1992 . Arthritis Rheum 1999; 42: 46-50 .

15.

Balluz L , Philen R , Ortega L et al. Investigation of systemic lupus erythematosus in Nogales, Arizona . Am J Epidemiol 2001; 154: 1029-1036 .

16.

Lopez P , Mozo L , Gutierrez C , Suarez A. Epidemiology of systemic lupus erythematosus in a nothern Spanish population: gender and age influence on immunologic features . Lupus 2003; 12: 860-865 .

17.

Middleton GD , McFarlin JE , Lipsky PE. The prevalence and clinical impact of fibromyalgia in SLE . Arthritis Rheum 1994; 37: 1181-1188 .

18.

Gladman DD , Urowitz MB , Gough J , MacKinnon A. Fibromyalgia is a major contributor to quality of life in lupus . J Rheumatol 1997; 24: 2145-2148 .

19.

Wang B , Gladman DD , Urowitz MB. Fatigue in lupus is not correlated with disease activity . J Rheumatol 1998; 25: 892-895 .

20.

Esdaile JM , Abrahamowicz M , Grodzicky T et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus . Arthritis Rheum 2001; 44: 2331-2337 .

21.

Manzi S , Meilahn EN , Rairie JE et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study . Am J Epidemiol 1997; 145: 408-415 .

22.

Gladman DD , Ginzler E , Goldsmith C et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus . Arthritis Rheum 1996; 39: 363-369 .

23.

Gladman DD , Urowitz MB. The SLICC/ACR damage index: progress report and experience in the field . Lupus 1999; 8: 632-637 .

24.

SPSS for windows 11.0. SPSS Inc, Chicago, 2003. www.spss.com (last accessed 2 June 2004)

25.

Tan EM , Cohen AS , Fries JF et al. Special article: the 1982 revised criteria for the classification of systemic lupus erythematosus . Arthritis Rheum 1982; 25: 1271-1277 .

26.

Arnett FC , Edworthy SM , Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis . Arthritis Rheum 1988; 31: 315-324 .

27.

Steinbrocker O , Traeger CH , Battermann RC. Therapeutic criteria in rheumatoid arthritis . JAMA 1949; 140: 659-662 .

28.

Lautenschlaeger J , Mau W , Kohlmann T et al. Vergleichende Evaluation einer deutschen Version des Health Assessment Questionnaires (HAQ) und des Funktionsfragebogens Hannover (FFbH). [Comparative evaluation of a German version of the Health Assessment Questionnaire (HAQ) and the Hanover Functional Status Questionnaire (HFSQ)] . Z Rheumatol 1997; 56: 144-155 .

29.

Milligan SE , Hom DL , Ballou SP , Persse LJ , Svilar GM , Coulton CJ. An assessment of the Health Assessment Questionnaire functional ability index among women with systemic lupus erythematosus . J Rheumatol 1993; 20: 972-976 .

30.

Zink A , Listing J , Klindworth C , Zeidler H for the German Collaborative Arthritis Centres . The National Database of the German Collaborative Arthritis Centres. Structure, aims, and patients . Ann Rheum Dis 2001; 60: 199-206 .

31.

Zink A , Listing J , Niewerth M , Zeidler H for the German Collaborative Arthritis Centres . The National Database of the German Collaborative Arthritis Centres—treatment of patients with rheumatoid arthritis . Ann Rheum Dis 2001; 60: 207-213 .

32.

Karlson EW , Daltroy LH , Lew RA et al. The relationship of socioeconomic status, race, and modifiable risk factors to outcomes in patients with systemic lupus erythematosus . Arthritis Rheum 1997; 40: 47-56 .

33.

Reveille JD , Bartolucci A , Alarcon GS. Prognosis in systemic lupus erythematosus. Negative impact of increasing age at onset, black race, and thrombocytopenia, as well as causes of death . Arthritis Rheum 1990; 33: 37-48 .

34.

Silman AJ. The changing face of rheumatoid arthritis: why the decline in incidence ? Arthritis Rheum 2002; 46: 579-581 .

35.

Doran MF , Pond GR , Crowson CS , O’Fallon M , Gabriel SE. Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty-year-period . Arthritis Rheum 2002; 46: 625-631 .

36.

Swaak AJ , Nossent JC , Bronsveld W et al. II. Observations on the occurrence of exacerbations in the disease course: Dutch experience with 110 patients studied prospectively . Ann Rheum Dis 1989; 48: 455-460 .

37.

Swaak AJ , Bronsveld W , Nieuwenhuys EJ , Nossent JC , Smeenk RJ. Systemic lupus erythematosus - changing disease patterns in the disease course. Dutch experience with 110 patients studied prospectively . Rheumatol Int 1991; 10: 241-244 .

38.

Stahl-Hallengren C , Jonsen A , Nived O , Sturfelt G. Incidence studies of systemic lupus erythematosus in Southern Sweden: increasing age, decreasing frequency of renal manifestations and good prognosis . J Rheumatol 2000; 27: 685-691 .

39.

Partridge AJ , Karlson EW , Daltroy LH et al. Risk factors for early work disability in systemic lupus erythematosus: results from a multicenter study . Arthritis Rheum 1997; 40: 2199-2206 .

40.

Gladman DD , Koh DR , Urowitz MB , Farewell VT. Lost-to-followup study in systemic lupus erythematosus (SLE) . Lupus 2000; 9: 363-367 .

41.

Drenkard C , Villa AR , Garcia-Padilla C , Perez-Vasquez ME , Alarcon-Segovia D. Remission of systemic lupus erythematosus . Medicine 1995; 75: 88-98 .

42.

Swaak AJ , van den Brink HG , Smeenk RJ et al. Systemic lupus erythematosus. Disease outcome in patients with a disease duration of at least 10 years: second evaluation . Lupus 2001; 10: 51-58 .

43.

Swaak AJ , van den Brink HG , Smeenk RJ et al. Systemic lupus erythematosus: clinical features in patients with a disease duration of over 10 years, first evaluation . Rheumatology (Oxford) 1999; 38: 953-958 .

44.

Wang C , Mayo NE , Fortin PR. The relationship between health related quality of life and disease activity and damage in systemic lupus erythematosus . J Rheumatol 2001; 28: 525-532 .